ArticleNanomedicine (London, England)2014
Heterogeneity in nanoparticles influences biodistribution and targeting.
Article in Nanomedicine (London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Targeting the ENO1 metabolic checkpoint via microenvironment-responsive nanotherapeutics promotes postinfarction cardiac repair.Science advances · 2026Article
- Macromolecular Cargo Encapsulation via In Vitro Assembly of Two-Component Protein Nanoparticles.Advanced healthcare materials · 2024Article
- Nanotherapeutic Heterogeneity: Sources, Effects, and Solutions.Small (Weinheim an der Bergstrasse, Germany) · 2024Review
- Catalytic antioxidant nanoparticles mitigate secondary injury progression and promote functional recovery in spinal cord injury model.Journal of controlled release : official journal of the Controlled Release Society · 2023Article
- Single Particle Chemical Characterisation of Nanoformulations for Cargo Delivery.The AAPS journal · 2023Review
- Perspectives for Improving the Tumor Targeting of Nanomedicine via the EPR Effect in Clinical Tumors.International journal of molecular sciences · 2023Review
- Sex-based differences of antioxidant enzyme nanoparticle effects following traumatic brain injury.Journal of controlled release : official journal of the Controlled Release Society · 2023Article
- Clinical Advances of siRNA-Based Nanotherapeutics for Cancer Treatment.Pharmaceutics · 2021Review
- Rationally Designed DNA Nanostructures for Drug Delivery.Frontiers in chemistry · 2020Review
- Evaluating accessibility of intravenously administered nanoparticles at the lesion site in rat and pig contusion models of spinal cord injury.Journal of controlled release : official journal of the Controlled Release Society · 2019Article
- Single Particle Automated Raman Trapping Analysis.Nature communications · 2018Article
- Lipid-modified G4-decoy oligonucleotide anchored to nanoparticles: delivery and bioactivity in pancreatic cancer cells.Scientific reports · 2016Article
- Inhibition of bone loss with surface-modulated, drug-loaded nanoparticles in an intraosseous model of prostate cancer.Journal of controlled release : official journal of the Controlled Release Society · 2016Article
- Control of polymeric nanoparticle size to improve therapeutic delivery.Journal of controlled release : official journal of the Controlled Release Society · 2015Review
- Clinical experiences with systemically administered siRNA-based therapeutics in cancer.Nature reviews. Drug discovery · 2015Review
- Flash Technology-Based Self-Assembly in Nanoformulation: From Fabrication to Biomedical Applications.Materials today (Kidlington, England)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
aimA large fraction of the administered dose of nanoparticles (NPs) localizes into nontarget tissue, which could be due to the heterogeneous population of NPs. MATERIALS &
methodsTo investigate the impact of the above issue, we simultaneously tracked the biodistribution using optical imaging of two different sized poly(d,l-lactide co-glycolide) NPs, which also varied in their surface charge and texture, in a prostate tumor xenograft mouse model.
resultsAlthough formulated using the same polymer and emulsifier concentration, small NPs were neutral (S-neutral-NPs), whereas large NPs were anionic (L-anionic-NPs). Simultaneous injection of these NPs, representing heterogeneity, shows significantly different biodistribution. S-neutral-NPs demonstrated longer circulation time than L-anionic-NPs (t1/2 = 96 vs 13 min); accounted for 75% of total NPs accumulated in the tumor; and showed 13-fold greater tumor to liver signal intensity ratio than L-anionic-NPs.
conclusionThe data underscore the importance of formulating nanocarriers of specific properties to enhance their targeting efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.